Y Intercept Hong Kong Ltd Has $734,000 Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)

Y Intercept Hong Kong Ltd raised its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 160.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 36,006 shares of the company’s stock after buying an additional 22,183 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Denali Therapeutics were worth $734,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of DNLI. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Denali Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after buying an additional 920 shares during the last quarter. Integrated Advisors Network LLC acquired a new position in shares of Denali Therapeutics during the third quarter worth approximately $283,000. VELA Investment Management LLC acquired a new position in shares of Denali Therapeutics during the third quarter worth approximately $455,000. Principal Financial Group Inc. lifted its holdings in shares of Denali Therapeutics by 13.8% during the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock worth $36,076,000 after buying an additional 149,939 shares during the last quarter. Finally, AIA Group Ltd lifted its holdings in shares of Denali Therapeutics by 7.9% during the third quarter. AIA Group Ltd now owns 74,815 shares of the company’s stock worth $2,179,000 after buying an additional 5,471 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently commented on DNLI. Baird R W upgraded Denali Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 7th. Deutsche Bank Aktiengesellschaft began coverage on Denali Therapeutics in a research note on Tuesday, February 11th. They issued a “buy” rating and a $31.00 target price for the company. Stifel Nicolaus upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a research note on Monday, December 16th. JPMorgan Chase & Co. cut their target price on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a research note on Tuesday, January 7th. Finally, Robert W. Baird began coverage on Denali Therapeutics in a research note on Tuesday, January 7th. They issued an “outperform” rating and a $31.00 target price for the company. Two investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Denali Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $37.42.

Insider Transactions at Denali Therapeutics

In other news, insider Carole Ho sold 12,255 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $20.22, for a total transaction of $247,796.10. Following the sale, the insider now owns 178,580 shares in the company, valued at approximately $3,610,887.60. This represents a 6.42 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Vicki L. Sato sold 3,080 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total value of $64,402.80. Following the completion of the transaction, the director now owns 107,976 shares in the company, valued at approximately $2,257,778.16. This represents a 2.77 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 47,940 shares of company stock worth $973,442. Insiders own 7.90% of the company’s stock.

Denali Therapeutics Stock Performance

Shares of DNLI stock opened at $16.56 on Friday. The stock’s fifty day moving average is $21.38 and its 200-day moving average is $24.59. The stock has a market capitalization of $2.38 billion, a PE ratio of -6.00 and a beta of 1.43. Denali Therapeutics Inc. has a 52 week low of $14.56 and a 52 week high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.08. As a group, analysts forecast that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.